Processing of the laminin-5 (Ln-5) ␥2 chain by membrane-type-1 matrix metalloproteinases (MT1-MMP) promotes migration and invasion of epithelial and tumor cells. We previously demonstrated that MT1-MMP cleaves the rat ␥2 chain at two sites, producing two major C-terminal fragments of 100 (␥2) and 80 (␥2x) kDa and releasing a 30-kDa fragment containing epidermal growth factor (EGF)-like motifs (domain III (DIII) fragment). The DIII fragment bound the EGF receptor (EGF-R) and stimulated cell scattering and migration. However, it is not yet clear whether human Ln-5 is processed in a similar fashion to rat Ln-5 because one of the two MT1-MMP cleavage sites present in rat ␥2 is not found in human ␥2. To identify the exact cleavage site for MT1-MMP in human Ln-5, we purified both the whole molecule as well as a monomeric form of human ␥2 that is frequently expressed by malignant tumor cells. Like rat Ln-5, both the monomer of ␥2, as well as the ␥2 derived from intact Ln-5, were cleaved by MT1-MMP in vitro, generating C-terminal ␥2 (100 kDa) and ␥2x (85 kDa) fragments and releasing DIII fragments (25 and 27k Da). In addition to the conserved first cleavage site used to generate ␥2, two adjacent cleavage sites (Gly 559 -Asp 560 and Gly 579 -Ser 580 ) were found that could generate the ␥2x and DIII fragments. Two of the three EGF-like motifs present in the rat DIII fragment are present in the 27-kDa human fragment, and like the rat DIII, this fragment can promote breast carcinoma cell migration by engaging the EGF-R. These results suggest that MT1-MMP processing of Ln-5 in human tumors may stimulate the EGF-R, resulting in increased tumor cell scattering and migration that could possibly increase their metastatic potential.
Laminin-5 (Ln-5), 1 a major component of the basement membrane, is a heterotrimer composed of ␣3, ␤3, and ␥2 subunits (1, 2) . Migration and scattering of epithelial and tumor cells are induced by proteolytic processing of the ␥2 chain of Ln-5. The ␥2 chain is a 140-kDa polypeptide and forms a triple helix with the other subunits at its C-terminal (see Fig. 1A ) (3, 4) . Processing of the ␥2 chain occurs at the N terminus generating two major C-terminal fragments of 100 (␥2Ј) and 80 (␥2x) kDa (see Fig. 1A ), and this processing has been observed in different species including humans and rodents (3, 4) . Because of the limited availability of purified Ln-5, most biochemical studies in this area have been carried out using the rat protein. MT1-MMP and MMP-2 were identified as the proteases responsible for the second cleavage of the N terminus generating the ␥2x fragment (3, 4) . In contrast, only MT1-MMP cleaved the first site to generate the ␥2Ј fragment (5) . The two cleavage sites on the rat ␥2 chain were identified as Gly 434 -Asp 435 for ␥2Ј and Ala 586 -Leu 587 for ␥2x (3, 6) . Processing of the rat ␥2 chain at these two sites releases an internal fragment containing three of the four EGF-like motifs in domain III (DIII) (7) . Although Ln-5 does not stimulate the EGF receptor (EGF-R), the DIII fragment released has the ability to bind EGF-R and induce its phosphorylation (8) . Inhibition of the processing using MMP inhibitors or inhibition of EGF-R activity using specific kinase inhibitors abolished cell migration on Ln-5 (8) . Thus, the DIII fragment generated by this processing appears to play a major role in the observed biological effect of Ln-5 and MT1-MMP. This system seems to function in vivo as well because MT1-MMP-deficient mice showed significantly reduced processing of the ␥2 chain in the kidney, resulting in abnormalities terminal differentiation of the tubular epithelium (5) .
Processing of the ␥2 chain by MT1-MMP appears to play a critical roles in tumor growth and progression because the ␥2 chain is frequently expressed as a monomer in malignant tumors that express MT1-MMP (9, 10) . In addition, aggressive melanoma cells are known to form vascular-like networks (vascular mimicry) requiring expression of MT1-MMP and the ␥2 chain (11) . Treatment of these cells with a neutralizing antibody against MT1-MMP or antisense oligonucleotide against the ␥2 gene abrogated the mimicry (11) . It has also been reported that the ␥2Ј and ␥2x fragments in humans are similar in size to those in the rat (3, 4) , suggesting that the processing of the human ␥2 chain by MT1-MMP is similar to that of the rat.
However, a comparison of rat and human ␥2 sequences reveals that although the first site (Gly 434 -Asp 435 ) is conserved in humans, the second cleavage site of rat ␥2 (Ala 586 -Leu 587 ) is not. Thus, it is not known whether MT1-MMP directly cleaves the second site in addition to the first and generates ␥2x and the DIII fragment. Further confusion has been raised by two contradictory reports on this issue. Veitch et al. (12) reported that the human ␥2 chain cannot be processed by MT1-MMP even at the first site, which is conserved between rodents and humans. Instead of MT1-MMP, they reported that the astacin family of proteases, such as bone morphogenic protein-1 (BMP-1) and mammalian Tolloid-like metalloproteinases, cleave the ␥2 chain (12, 13) . On the other hand, Gilles et al. (14) reported that recombinant MT1-MMP induces processing of Ln-5 deposited in the extracellular matrix, although the cleavage sites were not identified, and it was not clear whether a DIII-like fragment was generated as a result of the processing.
In this manuscript, we have attempted to settle this controversy by identifying the cleavage sites on the human ␥2 chain cut for MT1-MMP. To this end, we purified the ␥2 chain either as a monomer or as a heterotrimer (Ln-5) from human cancer cell lines. Incubation of the purified ␥2 chain and Ln-5 with a recombinant catalytic fragment of MT1-MMP generated the two C-terminal fragments (␥2Ј and ␥2x) and released DIII-like fragments functionally. By purifying the ␥2x fragment, two adjacent cleavage sites were determined. In addition, the ␥2 monomeric chain that is expressed in human malignant tumors show greater sensitivity to MT1-MMP than the heterotrimer form of Ln-5.
MATERIALS AND METHODS
Cells and Cell Culture-MKN45, a human gastric carcinoma cell line, was provided by the Japanese Collection of Research Bioresources (Tokyo, Japan). Mum2B, a human melanoma cell line, was a gift from Professor Mary Hendrix, University of Iowa, Iowa City, IA. STKM-1, a human gastric carcinoma cell line, was obtained from Dr. Shunsuke Yanoma, Kanagawa Cancer Center, Research Institute, Yokohama, Japan. All cell lines were cultured at 37°C in a humidified atmosphere of 5% CO 2 , 95% air. Dulbecco's modified Eagle's medium or RPMI 1640 medium (Sigma) supplemented with 10 mM HEPES, 1.2 mg/ml of NaHCO 3 , and 2 mM glutamate was used as basal medium and supplemented with 10% fetal bovine serum (Irvine Scientific, Irvine, CA).
SDS-PAGE and Western Blotting-The method for SDS-PAGE was described in our previous report (4) . The Western blotting was performed as reported (4) . Serum-free conditioned medium was collected from confluent cultures of cancer cells incubated for 2 days in serumfree medium. The serum-free conditioned medium was concentrated about 30-fold with ammonium sulfate at 80% saturation as described in our previous report (4) . The cell lysate was prepared with 20 mM Tris-HCl, 1% Triton X-100, 0.005% Brij-35. The protein concentration was measured with a Bio-Rad dye binding kit using bovine serum albumin as a standard.
Purification of Human Laminin-5 and Laminin ␥2 Monomer-Human Ln-5 and the laminin ␥2 monomer (Ln ␥2) were purified using anti-human Ln ␥2 monoclonal antibody (D4B5)-conjugated immunoaffinity chromatography from serum-free conditioned medium of the STKM-1 and Mum2B cell lines, respectively. The purification procedure and other experimental conditions were reported previously (4) .
N-terminal Sequencing-Automated N-terminal amino acid sequencing was performed with an Applied Biosystems model 419A protein sequencer (15) .
Cleavage of Ln-5 ␥2 and Monomeric Ln ␥2 by MT1-MMP in VitroPurified Ln-5 (1.5 g) or Ln ␥2 (0.5 g) was digested with recombinant MT1-MMP at a given concentration for 18 h at 37°C in 50 mM Tris (pH 7.5), 0.005% Brij-35, 0.1% CHAPS, and 10 mM CaCl 2 , electrophoresed with a 4 -20% gradient on SDS-PAGE gel under reducing conditions, and analyzed by Western blotting with a polyclonal antibody against domain III of Ln ␥2 (2778). The methods and conditions are described in previous reports (4) .
Transfection of MT1-MMP Expression Vector into
Cancer CellsTransfection with the pSG-MT1-MMP vector (1 g/5 ϫ 10 5 cells seeded in each well of 6-well plates) was done with the FuGene TM 6 reagent as recommended. After 2 days of transfection, the conditioned medium and cellular lysate were collected and analyzed by Western blotting for Ln ␥2 and its proteolytic fragments. The transfection procedure and experimental conditions were reported elsewhere (16) .
Expression and Purification of Human Recombinant DIII (rDIII) Fragment-Total RNA from STKM-1 (human gastric carcinoma cell line) was subjected to reverse transcription-PCR, and a gene encoding human Ln ␥2 chain was obtained. A gene fragment (435 bp) corresponding to the coding region for Asp 435 -Gly 579 was then amplified by PCR, fused with a FLAG coding sequence at the 3Ј end, and subcloned into the pCDNA 3.1 (ϩ) mammalian expression vector (Invitrogen). The expression plasmid was transfected into COS-7 cells, and the recombinant rDIII protein was expressed as a secreted form. rDIII protein that accumulated in the serum-free conditioned medium was purified by two series of column chromatography, an affinity column conjugated with anti-FLAG mAb (M2) and an anion-exchange HPLC on a QAE-825 column. The purified rDIII fragment was confirmed by SDS-PAGE and Western blotting.
Transwell Migration Assay-Cell migration assays were performed using Transwell chambers as described in our previous report (5) . Briefly, the filter undersides were coated with human Ln-5 (500 ng/ml) overnight at 4°C, blocked with 5% milk, phosphate-buffered saline, 0.05% Tween 20 for 2 h at room temperature, washed with phosphatebuffered saline twice, and used for cell migration assays. MDA-MB-231 cells were resuspended in Dulbecco's modified Eagle's medium and 0.1% bovine serum albumin in the absence or presence of human rDIII protein (1.3 M) and were seeded into the upper chamber at 20,000 cells/Transwell chamber. After an 8-h incubation with/without an antihuman EGF-R neutralizing antibody (10 g/ml) (LA-1) (Upstate Group, Inc, Charlottesville, VA), cells on the upper filter were scrapped and washed with phosphate-buffered saline three times, and then migrating cells on the lower filter were fixed with 100% MeOH and stained with 0.25% crystal violet, 20% MeOH for 15 and 30 min, respectively. Each bar represents the mean Ϯ S.D. for cell migration in three wells.
Reagents-Monoclonal antibody to human ␤-actin and polyclonal antibody to human BMP-1 were purchased from Chemicon International Inc. (Temecura, CA). Immobilon membranes were from Millipore (Bedford, MA). The transmigration chamber was from Corning-Corster (Corning, NY). Transmembrane domain-deleted recombinant MT1-MMP, polyclonal antibody against rat Ln ␥2 (2778), and monoclonal antibody to MT1-MMP were produced by our laboratories (3, 17, 18) .
RESULTS

Purification of Human Laminin-5 and Laminin ␥2
Monomer-The human cancer cell lines Mum2B and STKM-1 express the ␥2 chain as both a monomer and a heterotrimer, Ln-5, respectively. Serum-free conditioned medium of the cells was used to purify both forms of the ␥2 chain using an immunoaffinity column conjugated with a monoclonal antibody (D4B5) against the DIII domain of rat ␥2. The purified preparation from Mum2B cells contained one major (140 kDa) and two minor (280 and 100 kDa) polypeptides as detected by silver staining in Fig. 1B . Based on previous studies, the 140-kDa protein corresponded to the intact ␥2 chain, and the 280-kDa protein is presumably a dimer. The smaller band (100 kDa) corresponded to ␥2Ј cleaved at the first site, and the very weak band (85 kDa) corresponded to ␥2x cleaved at the second site (Fig. 1, A and B) . On the other hand, the preparation from STKM-1 cells contained ␣3 (160-kDa) and ␤3 (135-kDa) chains in addition to ␥2 (140 and 100 kDa). However, most of the ␥2 chain was detected as ␥2Ј, and the amount of intact ␥2 chain was negligible (Fig. 1B) . A very faint band corresponding to ␥2x was also detected.
Processing of Human Ln ␥2 Chain by MT1-MMP-The Ln ␥2 chain and ␥2Ј fragment were also detected by Western blotting using a polyclonal antibody against the rat DIII domain (Fig. 2,  A and B) . A fully processed ␥2x fragment was weakly detectable by the antibody, although the amount of DIII fragment was negligible in these preparations (Fig. 2 , see MT1-MMP 0 nM). The results presumably indicate that the mAb D4B5 used for the preparation recognizes the C-terminal part of the DIII domain, and this portion is not included in the clipped DIII fragment as illustrated in Fig. 2C . To examine whether MT1-MMP cleaves ␥2 and ␥2Ј, purified protein samples were incubated with increasing amounts of a catalytic fragment of human MT1-MMP. The amount of ␥2 monomer decreased and that of ␥2x and the DIII fragment increased dependent on the concentration of MT1-MMP (Fig. 2A, from 4 to 20 nM) . Thus, the human Ln ␥2 chain can be cleaved by MT1-MMP like its rat counterpart. The amount of ␥2Ј did not change significantly presumably because of the balance between production and further processing. The ␥2 chain in Ln-5 was also processed into ␥2x by MT1-MMP, and the DIII fragment was generated (Fig. 2B) . However, it is of note that the processing of the ␥2 chain in Ln-5 requires 10 times more MT1-MMP than the processing of the single chain form. Thus, the two forms of the ␥2 chain differ in their susceptibility to MT1-MMP.
Since the first cleavage site identified for the rat ␥2 chain is conserved, along with its flanking sequences, in humans (Fig.  2C) , it is most likely that cleavage to generate the ␥2Ј fragment occurs at this site. Thus, we tried to identify the second cleavage site that generates ␥2x. The ␥2x fragment was extracted from the polyacrylamide gel and sequenced. Two N-terminal sequences were identified in the ␥2x preparation, Asp-Pro-LeuAla and Ser-Glu-Pro-Val. Thus, the two cleavage sites were identified as Gly 559 -Asp 560 and Gly 579 -Ser 580 (Fig. 2C) . Although the Gly 559 -Asp 560 sequence is not conserved in rats, Gly 579 -Ser 580 is present in its flanking sequences (Fig. 2C) , which, although unreported, may be a cleavage site for the rat ␥2 chain.
The human DIII fragments are calculated to be 152 and 145 amino acids long, respectively, and presumably correspond to the 27-and 25-kDa bands in Fig. 2, A and B . Thus, human ␥2 fragments are generated by MT1-MMP as in rodents.
Human DIII Fragment Stimulates Carcinoma Cell Migration-We previously described that the rat DIII fragment contained three EGF-like motifs and promoted cell migration by engaging the EGF-R (8). As the human DIII fragment only contained two of the three motifs (Figs. 1A and 2C ), we attempted to confirm whether the human DIII fragment (Asp 435 -Gly 579 ) retained its activity to stimulate EGF-R. To do this, we expressed a secreted form of the recombinant rDIII protein with a FLAG tag at the C terminus in COS-7 cells. The rDIII fragment was purified from the serum-free conditioned medium using anti-FLAG antibody and subsequently by an anionexchange HPLC. The final preparation contained a 27-kDa single protein band as detected by silver staining after SDS-PAGE (Fig. 3A, left) , and the band reacted with anti-FLAG M2 antibody (Fig. 3A, right) .
The effect of the rDIII on migration of MDA-MB-231 cells was analyzed using a Transwell chamber. Addition of human rDIII (1.3 M) resulted in a 1.5-fold increase in migration on Ln-5 (Fig, 3B ) and this effect was completely abolished by a neutralizing antibody against EGF-R, LA-1. Thus, the two EGF-like motifs retained in the human DIII fragment appear to be sufficient to induce EGF-R-dependent cell migration.
Cell-mediated Processing of the Human Ln ␥2 Chain by MT1-MMP-To examine whether MT1-MMP is responsible for cellmediated processing of the human ␥2 chain, MT1-MMP was transiently expressed into Mum2B cells, and conditioned media was analyzed by Western blotting (Fig. 4A) . Untransfected Mum2B cells express MT1-MMP at a low level and constitutively release C-terminal fragments of ␥2 as well. Forced expression of MT1-MMP increased the amount of ␥2Ј and ␥2x fragments. To confirm that the ␥2 chain of in Ln-5 is processed from the intact Ln-5 molecule by MT1-MMP in a cell-mediated manner, we used human gastric carcinoma MKN45 cells. MKN45 cells produce Ln-5 containing only an intact form of the ␥2 chain (Fig. 4B) , and they do not express endogenous MT1-MMP at detectable levels as expected from the low levels of ␥2 processing. Expression of MT1-MMP in the cells resulted in a significant amount of the ␥2Ј fragment, although little ␥2x was MT1-MMP cleaves the rat Ln ␥2 chain at two sites (first and second cleavage sites from the N terminus) indicated by small arrows and produces two C-terminal proteolytic fragments, ␥2Ј (100 kDa) and ␥2x (80 kDa) (large arrow). Three EGF-like motifs (gray circle) exist in domain III in the short arm of ␥2 and are excised by MT1-MMP (large arrow) (5, 8) . B, purified human Ln ␥2 proteins from Mum2B (left) and STKM-1 (right). Ln ␥2 was purified from the culture medium of the cells, and purification was performed using an immunoaffinity column conjugated with mAb D4B5. A, purified human rDIII was analyzed by SDS-PAGE, and protein was detected by silver staining (left lane). After the separated protein was transferred to a nitrocellulose membrane, Western blotting (WB) was carried out using anti-FLAG M2 antibody (right lane). B, the human rDIII fragment was tested to determine whether it promotes MDA-MB-231 cell migration. Cells were seeded on the Ln-5-coated Transwell membrane and incubated for 8 h at 37°C (control (Cont)). The cells that migrated to the lower surface of the membrane were counted as described under "Materials and Methods." The rDIII protein (1.3 M), a neutralizing antibody (LA-1) against EGF-R (10 g/ml), or both were added to the lower chamber and incubated for 8 h. Results were presented as percentage of the control. detected at least under these conditions (Fig. 4A) . The processing was inhibited by 10 M MMP inhibitor BB94 (data not shown). Thus, the cell-associated form of MT1-MMP promotes the processing of both forms of the human ␥2 chain.
To determine whether there was a correlation between the expression levels of processing enzymes and Ln-5 processing, we assessed whether there was a correlation between endogenous MT1-MMP and the amount of cleavage observed. Ln-5 produced by STKM-1 cells and Ln-5 produced by Mum2B cells were both found in the cleaved form, and the Ln-5 in the STKM-1 cells contained only a small amount of intact ␥2 chain, whereas most of the ␥2 chains were detected as processed forms (Fig. 1B) . All three cell lines were analyzed by Western blotting with an antibody to MT1-MMP. MT1-MMP was detected in Mum2B cells but not in STKM-1 or MKN45 cells (Fig. 4C) . As BMP-1 has also been reported as a potential processing enzyme for Ln-5 (13), we determined whether it was found in the cells. STKM-1 (Fig. 4C ) cells were the only line to express this enzyme. Thus, BMP-1 appears to be responsible for the processing by the cells, and MT1-MMP appears to be responsible for that by Mum2B cells.
DISCUSSION
This study was performed due to the debate over the ability of MT1-MMP to cleave the human Ln ␥2 chain. We demonstrated that when monomeric or Ln-5 forms of the human ␥2 chain were purified and incubated with MT1-MMP, two major C-terminal fragments, ␥2Ј and ␥2x, were formed as reported for rat Ln-5. The first cleavage, which generates ␥2Ј, presumably occurs at the same site as rat ␥2 because the cutting site, including flanking sequences, is well conserved between the two species. At the location of the second cleavage sites, which generates the ␥2x fragment, we identified two adjacent sites (Gly 559 -Asp 560 and Gly 579 -Ser 580 ). Since the sites are close together, the two ␥2x bands could not be separated clearly by SDS-PAGE (Fig. 2, A and B) . This cleavage at the two different sites resulted in the formation of two DIII fragments (25 and 27 kDa) by MT1-MMP.
The Ln ␥2 chain is frequently expressed in malignant human tumors. Using the human cell line Mum2B, we purified a monomeric form of ␥2 and compared the processing of the monomer by MT1-MMP with that of Ln-5. Interestingly, the monomer was 10 times more sensitive to MT1-MMP than the Ln-5 form. Since the ␥2 monomer is frequently expressed together with MT1-MMP in malignant tumors, a similar processing of the ␥2 chain may be occurring in tumors. This result supports the previous observations that both ␥2 and MT1-MMP were required for melanoma cells to show vascular mimicry (11) . We have also found that rat Ln-5 showed greater sensitivity to MT1-MMP than human Ln-5 (data not shown). The relatively resistant nature of human Ln-5 may be why Veitch et al. (12) could not detect its processing by MT1-MMP. It is not clear whether the difference in sensitivity affects the biological outcome mediated by Ln-5 and MT1-MMP in humans significantly.
The second cleavage site, which generates the rat ␥2x fragment, is not conserved in humans (3, 6) , and two new cleavage sites were identified for human ␥2x. Although one site (Gly 559 -Asp 560 ) is not conserved in the rat sequence, the other site (Gly 579 -Ser 580 ) is. Thus, in addition to the rat ␥2x site (Ala 586 -Leu 587 ) reported previously, the conserved second site (Gly 558 -Ser 559 ) in rat Ln ␥2 may also be cleaved by MT1-MMP. Cleavage at the first and second sites in human Ln ␥2 generates shorter DIII fragments than in the rat (7 and 27 amino acids, respectively). Although the 27-kDa human DIII fragment retains only two of the three EGF-like motifs present in the in rat DIII fragment (7, 8) , it induced EGF-R-dependent carcinoma cell migration (Fig. 3B) . Thus, the human DIII fragment appears to function as an EGF-R ligand.
We also examined the expression of MT1-MMP and BMP-1 in three human tumor cell lines that produce ␥2 as either an intact or a processed form. Mum2B cells expressed MT1-MMP and produced processed forms of ␥2. STKM-1 cells produced Ln-5 containing processed forms of the ␥2 fragments and expressed BMP-1, another candidate for a protease that processes human Ln-5 (5, 12, 13) but not MT1-MMP. MKN45 cells that produce Ln ␥2 as an intact form expressed neither MT1-MMP nor BMP-1. Enforced expression of MT1-MMP in MKN45 cells induced cell-mediated processing of the ␥2 chain in Ln-5. Thus, multiple proteases including MT1-MMP and BMP-1 appear to mediate processing of the ␥2 chain, and the proteases responsible for the processing may differ depending on cell type and tissue. For example, although the processing of Ln ␥2 in kidney and lung is significantly reduced in MT1-MMP-deficient mice (5), such a reduction was not evident in other organs. On the other hand, mice lacking both BMP-1 and mammalian Tolloid-like metalloproteinases show reduced processing of Ln ␥2, particularly in skin (12) , although it is not clear whether this occurs in other tissues as well.
In conclusion, human Ln ␥2 is processed by MT1-MMP and generates DIII fragments containing at least two EGF-like motifs. Moreover, recombinant DIII fragment significantly increases cancer cell migration activity by engaging EGF-R. The monomeric form is 10 times more sensitive to MT1-MMP than the ␥2 chain in Ln-5. Thus, MT1-MMP can act as a processing enzyme for both human and rat ␥2 and presumably promotes cell migration and invasion through the action of the released DIII fragment (8) .
